Walgreens continues to shed stake in Cencora as it looks to bolster turnaround
Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.
All You Need to Know About Cencora (COR) Rating Upgrade to Buy
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pharma giant Cencora is alerting millions about its data breach
Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.
Walgreens Sells Another Stake In Distributor Cencora For $1.1 Billion
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billion, which will be used “primarily for debt paydown and general corporate purposes.”
Walgreens further reduces stake in Cencora
Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.
Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora says additional data stolen in February cyberattack
U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Eric Percher - Nephron Research Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Daniel Grosslight - Citi George Hill - Deutsche Bank Stephanie Davis - Barclays Eric Coldwell - Baird Kevin Caliendo - UBS Operator Good morning and good afternoon, ladies and gentlemen. Welcome to the Cencora Q3 Earnings Call.
Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago.
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
